Cardiac Markers Market Size, Share, Trends, Growth Outlook

Cardiac Markers Market is estimated to increase at a growth rate of 9.8% CAGR over the forecast period from 2024 to 2030.

The global Cardiac Markers Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Type (Troponin, B-Type Natriuretic Peptide, Creatine Kinase MB, Myoglobin, Others), By Indication (Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Others), By End-User (Hospitals, Diagnostic Laboratories, Point-of-care Testing Facilities, Others).

An Introduction to Cardiac Markers Market in 2024

The Cardiac Markers Market focuses on diagnostic biomarkers and assays used for assessing cardiac health, myocardial damage, and risk stratification in patients with cardiovascular diseases. Cardiac markers include troponins, creatine kinase-MB (CK-MB), myoglobin, and natriuretic peptides, providing valuable information on myocardial infarction, heart failure, and other cardiac conditions. In 2024, this market emphasizes high-sensitivity assays, point-of-care testing, and multi-marker panels for early detection, prognostic assessment, and monitoring of cardiac events, contributing to improved patient management and outcomes.

Cardiac Markers Market Competitive Landscape

The global Cardiac Markers Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Cardiac Markers Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Cardiac Markers Industry include- Abbott Laboratories, bioMérieux SA, Bio-Rad Laboratories, Creative Diagnostics, Danaher Corp, Diazyme Laboratories Inc, Quidel Corp, F. Hoffmann-La Roche Ltd, Siemens AG, Thermo Fisher Scientific Inc, Trinity Biotech Plc.

Cardiac Markers Market Trend: Rapid Adoption of Point-of-Care Testing

A significant trend in the Cardiac Markers market is the rapid adoption of point-of-care testing (POCT) for cardiac biomarkers. POCT devices offer the advantage of providing rapid and accurate results at the patient's bedside or in outpatient settings, allowing for immediate diagnosis and treatment decisions. With advancements in technology, POCT devices for cardiac markers have become increasingly portable, user-friendly, and capable of detecting multiple biomarkers simultaneously. This trend is driven by the growing emphasis on early detection and management of cardiovascular diseases, as well as the need for timely assessment of patients presenting with acute coronary syndrome and heart failure symptoms.

Cardiac Markers Market Driver: Increasing Incidence of Cardiovascular Diseases

A key driver for the Cardiac Markers market is the rising incidence of cardiovascular diseases (CVDs) worldwide. Conditions such as myocardial infarction, heart failure, and stroke continue to be leading causes of morbidity and mortality globally. The early and accurate diagnosis of cardiac conditions is crucial for guiding appropriate treatment strategies and improving patient outcomes. Cardiac markers, such as troponins, creatine kinase-MB (CK-MB), and brain natriuretic peptide (BNP), play a vital role in the diagnosis, risk stratification, and monitoring of patients with suspected or confirmed CVDs. As the burden of CVDs continues to increase, the demand for cardiac marker testing is expected to rise, driving market growth.

Cardiac Markers Market Opportunity: Expansion of Biomarker Panels and Personalized Medicine

An opportunity for market expansion in the Cardiac Markers market lies in the expansion of biomarker panels and the adoption of personalized medicine approaches. While traditional cardiac markers like troponins remain essential for diagnosing acute coronary syndromes, there is growing interest in exploring novel biomarkers and multi-marker panels to improve risk stratification and prognosis prediction for cardiovascular events. Additionally, the concept of personalized medicine aims to tailor treatment strategies based on individual patient characteristics, including biomarker profiles, genetics, and comorbidities. By incorporating emerging biomarkers and leveraging advances in molecular diagnostics, there is potential to enhance the accuracy and specificity of cardiac marker testing, leading to more precise risk assessment and targeted therapeutic interventions for patients with cardiovascular diseases.

Market Share Analysis: Troponin is the fastest growing segment in the Cardiac Markers industry

Troponin emerges as the fastest-growing segment in the realm of Cardiac Markers. Troponin is a sensitive and specific marker of myocardial injury and is widely used for diagnosing acute myocardial infarction (AMI) and other acute coronary syndromes (ACS). The rising prevalence of cardiovascular diseases, coupled with the increasing adoption of troponin assays in routine clinical practice for early diagnosis and risk stratification of cardiac events, is driving the growth of the troponin market. Additionally, advancements in troponin assay technology, such as high-sensitivity troponin assays, enable earlier detection of myocardial injury, leading to better patient management and outcomes. With the growing emphasis on early detection and management of cardiovascular conditions, the troponin market is poised for significant expansion in the foreseeable future.

Cardiac Markers Market Segmentation

By Type
Troponin
B-Type Natriuretic Peptide
Creatine Kinase MB
Myoglobin
Others
By Indication
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Others
By End-User
Hospitals
Diagnostic Laboratories
Point-of-care Testing Facilities
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)

Cardiac Markers Companies

Abbott Laboratories
bioMérieux SA
Bio-Rad Laboratories
Creative Diagnostics
Danaher Corp
Diazyme Laboratories Inc
Quidel Corp
F. Hoffmann-La Roche Ltd
Siemens AG
Thermo Fisher Scientific Inc
Trinity Biotech Plc
* List not Exhaustive

Reasons to Buy the Cardiac Markers Market Study

• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Cardiac Markers Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Cardiac Markers Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.

TABLE OF CONTENTS

1 Introduction to 2024 Cardiac Markers Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain

2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations

3 Executive Summary
3.1 Global Cardiac Markers Market Size Outlook, $ Million, 2021 to 2030
3.2 Cardiac Markers Market Outlook by Type, $ Million, 2021 to 2030
3.3 Cardiac Markers Market Outlook by Product, $ Million, 2021 to 2030
3.4 Cardiac Markers Market Outlook by Application, $ Million, 2021 to 2030
3.5 Cardiac Markers Market Outlook by Key Countries, $ Million, 2021 to 2030

4 Market Dynamics
4.1 Key Driving Forces of Cardiac Markers Industry
4.2 Key Market Trends in Cardiac Markers Industry
4.3 Potential Opportunities in Cardiac Markers Industry
4.4 Key Challenges in Cardiac Markers Industry

5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Cardiac Markers Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook

6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts

7 Global Cardiac Markers Market Outlook by Segments
7.1 Cardiac Markers Market Outlook by Segments, $ Million, 2021- 2030
By Type
Troponin
B-Type Natriuretic Peptide
Creatine Kinase MB
Myoglobin
Others
By Indication
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Others
By End-User
Hospitals
Diagnostic Laboratories
Point-of-care Testing Facilities
Others
8 North America Cardiac Markers Market Analysis and Outlook To 2030
8.1 Introduction to North America Cardiac Markers Markets in 2024
8.2 North America Cardiac Markers Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Cardiac Markers Market size Outlook by Segments, 2021-2030
By Type
Troponin
B-Type Natriuretic Peptide
Creatine Kinase MB
Myoglobin
Others
By Indication
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Others
By End-User
Hospitals
Diagnostic Laboratories
Point-of-care Testing Facilities
Others
9 Europe Cardiac Markers Market Analysis and Outlook To 2030
9.1 Introduction to Europe Cardiac Markers Markets in 2024
9.2 Europe Cardiac Markers Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Cardiac Markers Market Size Outlook by Segments, 2021-2030
By Type
Troponin
B-Type Natriuretic Peptide
Creatine Kinase MB
Myoglobin
Others
By Indication
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Others
By End-User
Hospitals
Diagnostic Laboratories
Point-of-care Testing Facilities
Others
10 Asia Pacific Cardiac Markers Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Cardiac Markers Markets in 2024
10.2 Asia Pacific Cardiac Markers Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Cardiac Markers Market size Outlook by Segments, 2021-2030
By Type
Troponin
B-Type Natriuretic Peptide
Creatine Kinase MB
Myoglobin
Others
By Indication
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Others
By End-User
Hospitals
Diagnostic Laboratories
Point-of-care Testing Facilities
Others
11 South America Cardiac Markers Market Analysis and Outlook To 2030
11.1 Introduction to South America Cardiac Markers Markets in 2024
11.2 South America Cardiac Markers Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Cardiac Markers Market size Outlook by Segments, 2021-2030
By Type
Troponin
B-Type Natriuretic Peptide
Creatine Kinase MB
Myoglobin
Others
By Indication
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Others
By End-User
Hospitals
Diagnostic Laboratories
Point-of-care Testing Facilities
Others
12 Middle East and Africa Cardiac Markers Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Cardiac Markers Markets in 2024
12.2 Middle East and Africa Cardiac Markers Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Cardiac Markers Market size Outlook by Segments, 2021-2030
By Type
Troponin
B-Type Natriuretic Peptide
Creatine Kinase MB
Myoglobin
Others
By Indication
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Others
By End-User
Hospitals
Diagnostic Laboratories
Point-of-care Testing Facilities
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott Laboratories
bioMérieux SA
Bio-Rad Laboratories
Creative Diagnostics
Danaher Corp
Diazyme Laboratories Inc
Quidel Corp
F. Hoffmann-La Roche Ltd
Siemens AG
Thermo Fisher Scientific Inc
Trinity Biotech Plc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise

By Type
Troponin
B-Type Natriuretic Peptide
Creatine Kinase MB
Myoglobin
Others
By Indication
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Others
By End-User
Hospitals
Diagnostic Laboratories
Point-of-care Testing Facilities
Others